Neurocrine Biosciences
Yahoo Finance • last month
Exploring Three High Growth Tech Stocks in the United States
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance... Full story
Yahoo Finance • 2 months ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specificall... Full story
Yahoo Finance • 3 months ago
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors Wednesday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) topline data for its Phase 2 clinical study of NBI-1117568... Full story
Yahoo Finance • 3 months ago
Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)
On August 15, 2024, Director William Rastetter executed a sale of 14,250 shares of Neurocrine Biosciences Inc (NASDAQ:NBIX) as reported in the SEC Filing. Following this transaction, the insider now owns 37,491 shares of the company. The s... Full story
Yahoo Finance • 7 months ago
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Sco... Full story
Yahoo Finance • 8 months ago
Top 12 Stocks in George Soros’ Stock Portfolio
In this article, we discuss the top 12 stocks in George Soros’ stock portfolio. To skip the details on Soros’ life, investment philosophy, and his fund’s latest bets, go directly to the Top 5 Stocks in George Soros' Stock Portfolio. Billi... Full story
Yahoo Finance • 9 months ago
Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc
Richard Pops, a director at Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 15,000 shares in the company on February 20, 2024, according to a recent SEC Filing. Neurocrine Biosciences Inc is a biopharmaceutical company focused... Full story
Yahoo Finance • 9 months ago
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. The... Full story
Yahoo Finance • 9 months ago
Neurocrine Biosciences Full Year 2023 Earnings: EPS Beats Expectations
Neurocrine Biosciences (NASDAQ:NBIX) Full Year 2023 Results Key Financial Results Revenue: US$1.89b (up 27% from FY 2022). Net income: US$249.7m (up 62% from FY 2022). Profit margin: 13% (up from 10% in FY 2022). EPS: US$2.56 (up from US... Full story
Yahoo Finance • 10 months ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript February 7, 2024 Neurocrine Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). O... Full story
Yahoo Finance • 10 months ago
Neurocrine Biosciences Inc CFO Matt Abernethy Sells Company Shares
Neurocrine Biosciences Inc (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases and disorders, has reported an insider sell transaction. According to a recent SEC Filin... Full story
Yahoo Finance • 10 months ago
Neurocrine Biosciences Inc's Chief Legal Officer Sells Shares
Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), sold 10,000 shares of the company on January 22, 2024, according to a recent SEC Filing. The transaction was executed at a price of $139.86 per share, res... Full story
Yahoo Finance • 11 months ago
Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco. Kevin Gorman, Chie... Full story
Yahoo Finance • 11 months ago
13 High Growth Healthcare Stocks to Buy
In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story
Yahoo Finance • 11 months ago
Neurocrine Biosciences' (NASDAQ:NBIX) five-year earnings growth trails the 12% YoY shareholder returns
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the Neurocrine... Full story
Yahoo Finance • 11 months ago
Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc
Neurocrine Biosciences Inc (NASDAQ:NBIX), a prominent player in the biopharmaceutical industry, has recently witnessed a significant insider sell by its Chief Medical Officer, Eiry Roberts. On December 8, 2023, Eiry Roberts sold a substant... Full story
Yahoo Finance • last year
Steven Cohen's Point72 Asset Management Adjusts Portfolio, Notably Reduces Adobe Stake
Insights from the Latest 13F Filing Highlight Key Investment Changes Steven A. Cohen, the renowned investor at the helm of Point72 Asset Management, has made significant changes to his investment portfolio in the third quarter of 2023. Co... Full story
Yahoo Finance • last year
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved all patent litigation related to lawsuits resulting from A... Full story
Yahoo Finance • 2 years ago
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress
SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™ 4) of INGREZZA® (valbenazine) capsules evaluating global... Full story
Yahoo Finance • 2 years ago
Q4 2022 Voyager Therapeutics Inc Earnings Call
Participants Alfred W. Sandrock; President, CEO & Director; Voyager Therapeutics, Inc. Allen Nunnally; Chief Business Officer; Voyager Therapeutics, Inc. Peter P. Pfreundschuh; CFO; Voyager Therapeutics, Inc. Todd Carter; Chief Science... Full story
